- Home
- HRTX vs RNAC Comparison
HRTX vs RNAC Comparison
Compare HRTX & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- RNAC
- Stock Information
- Founded
- HRTX 1983
- RNAC 2007
- Country
- HRTX United States
- RNAC United States
- Employees
- HRTX N/A
- RNAC N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- RNAC Health Care
- Exchange
- HRTX Nasdaq
- RNAC Nasdaq
- Market Cap
- HRTX 276.1M
- RNAC 276.3M
- IPO Year
- HRTX 1987
- RNAC 2016
- Fundamental
- Price
- HRTX $1.35
- RNAC $10.05
- Analyst Decision
- HRTX Strong Buy
- RNAC Strong Buy
- Analyst Count
- HRTX 2
- RNAC 4
- Target Price
- HRTX $4.50
- RNAC $40.00
- AVG Volume (30 Days)
- HRTX 2.6M
- RNAC 48.4K
- Earning Date
- HRTX 08-08-2025
- RNAC 08-07-2025
- Dividend Yield
- HRTX N/A
- RNAC N/A
- EPS Growth
- HRTX N/A
- RNAC N/A
- EPS
- HRTX N/A
- RNAC N/A
- Revenue
- HRTX $149,694,000.00
- RNAC $1,026,000.00
- Revenue This Year
- HRTX $10.62
- RNAC N/A
- Revenue Next Year
- HRTX $12.99
- RNAC N/A
- P/E Ratio
- HRTX N/A
- RNAC N/A
- Revenue Growth
- HRTX 9.78
- RNAC N/A
- 52 Week Low
- HRTX $1.04
- RNAC $8.46
- 52 Week High
- HRTX $2.68
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- HRTX 36.48
- RNAC 34.71
- Support Level
- HRTX $1.33
- RNAC $10.50
- Resistance Level
- HRTX $1.43
- RNAC $11.80
- Average True Range (ATR)
- HRTX 0.07
- RNAC 0.56
- MACD
- HRTX 0.02
- RNAC -0.11
- Stochastic Oscillator
- HRTX 45.45
- RNAC 0.45
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.